These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38296559)

  • 1. In Silico Prediction of N-Nitrosamine Formation Pathways of Pharmaceutical Products.
    Tsuji G; Kurohara T; Shoda T; Yokoo H; Ito T; Masada S; Uchiyama N; Yamamoto E; Demizu Y
    Chem Pharm Bull (Tokyo); 2024; 72(2):166-172. PubMed ID: 38296559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Bioanalytical Method for Quantification of N-nitrosodimethylamine (NDMA) in Human Plasma and Urine with Different Meals and following Administration of Ranitidine.
    De Palma R; Patel V; Florian J; Keire D; Selaya D; Strauss DG; Rouse R; Matta MK
    J Pharm Sci; 2023 May; 112(5):1315-1323. PubMed ID: 36736776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nitrosamine Impurities in Pharmaceuticals: An Empirical Review of their Detection, Mechanisms, and Regulatory Approaches.
    Bhirud D; Agrawal G; Shah H; Patel A; Palkar MB; Bhattacharya S; Prajapati BG
    Curr Top Med Chem; 2024; 24(6):503-522. PubMed ID: 38321910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The competitive effect of different chlorination disinfection methods and additional inorganic nitrogen on nitrosamine formation from aromatic and heterocyclic amine-containing pharmaceuticals.
    Chen WH; Wang YH; Hsu TH
    Chemosphere; 2021 Mar; 267():128922. PubMed ID: 33190909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral intake of ranitidine increases urinary excretion of N-nitrosodimethylamine.
    Zeng T; Mitch WA
    Carcinogenesis; 2016 Jun; 37(6):625-634. PubMed ID: 26992900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simultaneous determination of low molecular weight nitrosamines in pharmaceutical products by fast gas chromatography mass spectrometry.
    Kalauz A; Tiringer KV; Horváth V; Kapui I
    J Chromatogr A; 2023 Oct; 1708():464323. PubMed ID: 37696123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analytical Method Capable of Quantifying Eight Nitrosamine Impurities from Five Different Commercially Available Metformin Formulations with Glipizide, Glibenclamide, Gliclazide, Evogliptin, and Glimepiride by Ultra High Performance Liquid Chromatography Tripple Quadrupole Mass Spectrometry.
    Solanki R; Wadhwana P; Patel R; Gayakvad B; Kothari C; Patel C
    J Pharm Sci; 2023 May; 112(5):1268-1276. PubMed ID: 36822274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Presence of nitrosamine impurities in medicinal products.
    Sedlo I; Kolonić T; Tomić S
    Arh Hig Rada Toksikol; 2021 Mar; 72(1):1-5. PubMed ID: 33787187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation and optimization of a HS-SPME-assisted GC-MS/MS method for monitoring nitrosamine impurities in diverse pharmaceuticals.
    Chang SH; Ho HY; Chang CC; Zang CZ; Hsu YH; Lin MC; Tseng SH; Wang DY
    J Pharm Biomed Anal; 2022 Nov; 221():115003. PubMed ID: 36095885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Full Evaporation Static Headspace Gas Chromatography Method with Nitrogen Phosphorous Detection for Ultrasensitive Analysis of Semi-volatile Nitrosamines in Pharmaceutical Products.
    Zheng J; Kirkpatrick CL; Lee D; Han X; Martinez AI; Gallagher K; Evans RK; Mudur SV; Liang X; Drake J; Buhler LA; Mowery MD
    AAPS J; 2022 Jan; 24(1):23. PubMed ID: 34993666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of nitrosamine contaminants in drug samples: Has the crisis been overcome?
    Schmidtsdorff S; Neumann J; Schmidt AH; Parr MK
    Arch Pharm (Weinheim); 2023 Feb; 356(2):e2200484. PubMed ID: 36461687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comprehensive review of sources of nitrosamine contamination of pharmaceutical substances and products.
    Akkaraju H; Tatia R; Mane SS; Khade AB; Dengale SJ
    Regul Toxicol Pharmacol; 2023 Mar; 139():105355. PubMed ID: 36792049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On the Risk of Nitrosamine Contamination During Drug Product Blister Packaging.
    Zheng J; Brookes A; Moser J; Pfeffer H; Smith A
    J Pharm Sci; 2023 Sep; 112(9):2321-2325. PubMed ID: 37478970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An update on the current status and prospects of nitrosation pathways and possible root causes of nitrosamine formation in various pharmaceuticals.
    Wichitnithad W; Nantaphol S; Noppakhunsomboon K; Rojsitthisak P
    Saudi Pharm J; 2023 Feb; 31(2):295-311. PubMed ID: 36942272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Demonstration of 20 pharmaceuticals and personal care products (PPCPs) as nitrosamine precursors during chloramine disinfection.
    Shen R; Andrews SA
    Water Res; 2011 Jan; 45(2):944-52. PubMed ID: 20950838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulatory Experiences with Root Causes and Risk Factors for Nitrosamine Impurities in Pharmaceuticals.
    Horne S; Vera MD; Nagavelli LR; Sayeed VA; Heckman L; Johnson D; Berger D; Yip YY; Krahn CL; Sizukusa LO; Rocha NFM; Bream RN; Ludwig J; Keire DA; Condran G
    J Pharm Sci; 2023 May; 112(5):1166-1182. PubMed ID: 36599405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nitrosamine Contamination in Pharmaceuticals: Threat, Impact, and Control.
    Tuesuwan B; Vongsutilers V
    J Pharm Sci; 2021 Sep; 110(9):3118-3128. PubMed ID: 33989680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Temperature-Dependent Formation of N-Nitrosodimethylamine during the Storage of Ranitidine Reagent Powders and Tablets.
    Abe Y; Yamamoto E; Yoshida H; Usui A; Tomita N; Kanno H; Masada S; Yokoo H; Tsuji G; Uchiyama N; Hakamatsuka T; Demizu Y; Izutsu KI; Goda Y; Okuda H
    Chem Pharm Bull (Tokyo); 2020 Oct; 68(10):1008-1012. PubMed ID: 32779580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nitrocellulose blister material as a source of N-nitrosamine contamination of pharmaceutical drug products.
    Golob N; Grahek R; Ross M; Roškar R
    Int J Pharm; 2022 Apr; 618():121687. PubMed ID: 35314277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NDMA Formation Due to Active Ingredient Degradation and Nitrite Traces in Drug Product.
    Golob N; Peterlin S; Grahek R; Roškar R
    J Pharm Sci; 2023 May; 112(5):1277-1286. PubMed ID: 36925105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.